Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals (VRTX 2.50%) and Crinetics ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

Vertex Pharmaceuticals will buy ⁠Crinetics ⁠Pharmaceuticals for a total ⁠equity value of about $10 billion, the companies said on Monday, adding ​treatments for rare hormonal diseases to its portfolio ...

A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...

NEW YORK – Germany’s Merck KGaA said Wednesday that it has entered into an agreement with Versant Ventures that funds the research activities of Versant-backed cardiology startup Saturnus Bio and ...

Germany’s Merck MRK-0.74%decrease; down pointing triangle KGaA said it struck a deal to buy U.S. life-sciences tools supplier Bio-Techne TECH-0.44%decrease; down pointing triangle for $11.3 billion, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal represents a 36% ...

June 25 (Reuters) - German ⁠drugmaker ⁠Merck KGaA said on Thursday it would ⁠buy U.S. firm Bio-Techne for $11.3 billion, its biggest deal in more than a decade, betting on demand for complex drug ...

Germany's Merck KGaA said it struck a deal to buy U.S. life-science tools supplier Bio-Techne for $11.4 billion, in an early move under its new chief executive to bulk up its life-sciences business.

GI Innovation announced on the 25th (local time) that it was selected to present at the 'Company Presentation' session, an ...

An early clinical study shows that a new oral drug is safe and well tolerated in patients with chronic heart failure. The study, led by researchers at Karolinska Institutet, has been published in The ...